

Development And Validation of UV Spectroscopic Method for the Estimation of Favipiravir in Bulk and Tablet Dosage Form

Harshitha M¹, Sowmya H. G², Naveen Kumar G. S³

¹2nd year M pharma, Student of Department of Pharmaceutical Analysis Bharathi College of Pharmacy, Mandya, Karnataka, India-571422

²Assistant Professor of Department of Pharmaceutical Analysis Bharathi College of Pharmacy, Mandya, Karnataka, India-571422

³Professor and HOD of Department of Pharmaceutical Analysis Bharathi College of Pharmacy, Mandya, Karnataka, India-571422

ABSTRACT:

Simple, precise and accurate area under curve spectroscopic method has been developed and validated for the estimation of Favipiravir in bulk and pharmaceutical dosage form. The drug shows maximum absorption (λ_{max}) at 361nm in 0.1N NaOH solution and Area under Curve [AUC] in absorption spectra were measured between the wavelength range 356 to 366nm which obeys Beer's law in the concentration range of 2-10 μ g/ml. The linearity study carried and regression coefficient was found to be 0.9982 and it has showed good linearity, precision during this concentration range. The % recovery was found to be 98.6-101.1. The LOD and LOQ were found to be 0.055 and 0.168 μ g/ml. The % relative standard deviation were found less than 2. According to ICH guidelines the method has been validated for linearity, precision, accuracy, robustness, ruggedness, LOD and LOQ. The developed and validated method can be successfully applied for reliable quantification of Favipiravir in bulk form and pharmaceutical dosage form.

KEYWORDS: Favipiravir, Area under curve spectroscopy, validation, pharmaceutical formulations.

INTRODUCTION:

Favipiravir is a well-known medication used to treat influenza, and its potential to treat COVID-19 is also being investigated. It is the first antiviral medication that can be taken orally for mild to moderate COVID-19. Studies that have previously been finished in China, Japan, and Russia have demonstrated that favipiravir is a possible treatment for this illness. Japan's Toyama Chemical created Favipiravir, is a derivative of pyrazine carboxamide that inhibits a variety of RNA viruses. It was initially reported to be a minimally cytotoxic, selective inhibitor of influenza virus replication. Favipiravir is thought to specifically target the RdRp catalytic region, blocking viral replication in cells and reducing infection. As a prodrug, favipiravir is phosphorylated and ribosylated to yield an active form known as favipiravir ribofuranosyl-5'-triphosphate (Favipiravir-RTP), which binds to RNA dependent RNA polymerase and inhibits viral replication by mimicking guanosine and adenosine for viral RNA-dependent RNA polymerase (RdRP), which prevents primer extension. Clinical research indicates that Favipiravir's

teratogenic properties make it inappropriate to recommend during pregnancy. When used orally, the medication reaches its maximal concentration after two hours and has a brief half-life of two to five hours. Favipiravir's plasma protein binding capability was discovered to be 54%.

Chemically favipiravir is 6-fluoro-3-hydroxypyrazine-2 carboxamide. Favipiravir is a pale-yellow powder available in crystalline solid form and it is soluble in organic solvents such as N, N-Dimethyl Formamide methanol, DMSO, NaOH, and even soluble in deionized water. Its molecular formula is $C_5H_4FN_3O_2$ and its molecular weight is 157.1g/mol and having melting point in the range of 187 - 193°C




Fig.1: Chemical structure of Favipiravir

Literature survey revealed that there were few analytical methods have been reported for the determination of favipiravir in pure drug and pharmaceutical dosage forms by using UV¹⁻⁵, HPLC⁶⁻¹³, RP-HPLC¹⁴⁻²⁴ and HPTLC²⁵ so far. The aim of present work is to develop and validate a novel, rapid, simple, precise and specific Area under curve UV Spectrophotometric method for estimation of favipiravir in bulk and tablet dosage form.

MATERIALS AND METHODS:

Instrument: UV-Visible double beam spectrophotometer, SHIMADZU (model UV-1700) with UV probe software. All weights were taken in analytical balance.

Chemicals: Favipiravir pure drug was obtained as a gift sample from Glenmark Pharmaceutical, Bengaluru and its pharmaceutical dosage favipiravir 20 tablets (favipir-200) labelled claim 200mg from local pharmacy manufactured by Mascot Health Series Pvt. Ltd.

Solvent: 0.1N NaOH is used as a solvent.

Selection of analytical wavelength: Appropriate dilutions of Favipiravir were prepared from standard stock solution and using spectrophotometer solution was scanned in the wavelength range 200-400nm. Area under Curve [AUC] in absorption spectra were measured between the wavelength range of 356 to 366nm as the wavelength for detection (Fig-2).

Preparation of standard stock solution: 100mg of Favipiravir was weighed accurately and transferred into 100ml volumetric flask and diluted in 0.1N NaOH up to mark. From this, the solution was further diluted into 100µg/ml and pipetted 0.2, 0.4, 0.6, 0.8, 1.0, and 1.2ml into 10ml individual volumetric flask and diluted in 0.1N NaOH up to mark, this gives 2, 4, 6, 8, 10, and 12µg/ml concentration.

Preparation of sample solution: 20 tablets of Favipiravir marketed formulations was weighed and powdered. A quantity of tablet powder equivalent to 100mg of Favipiravir was transferred into a 100ml of volumetric flask then it was diluted with 0.1N NaOH and made up to the mark.

METHOD AND VALIDATION:

The method was validated according to ICH guidelines²⁶⁻²⁸

RESULTS AND DISCUSSION:

Method: Area under curve spectroscopy.

Linearity: The linearity of an analytical method is its capacity to show the test results that are directly proportional to the concentration of the analyte in the sample within the range. The linearity was established in the range of 2-10µg/ml and Area under Curve [AUC] in absorption spectra were measured between the wavelength of 356 to 366nm as absorbance values are shown in table-1 (Fig-3). The calibration curve was prepared by plotting graph against the concentration and absorbance and therefore the graph shown in (Fig-4). Statistical parameter like slope, intercept, regression equation, correlation coefficient and Sandell’s sensitivity were determined. (table-2).

Precision: The precision of an analytical method expresses the closeness of a series of individual analyte measurements obtained from multiple sampling of the equivalent sample. Precision was determined by intra-day and inter-day study. Intra-day precision was determined by analysing the same concentration for six times in a same day. Inter-day precision was determined by analysing the same concentration daily for six days. (table-3).

Accuracy: The accuracy of an analytical method says that closeness of test results obtained by that method to the true value. To assess the accuracy of the developed method, recovery studies were carried out at three different levels as 50%, 100% and 150%. In which the formulation concentration kept constant and varied pure drug concentration. (table-4).

Ruggedness: The ruggedness is defined as the reproducibility of results when the method is performed under the variation in conditions. This includes different analyst, laboratories, instruments, temperature etc. Ruggedness was determined between different analyst, the value of %RSD was found to be less than 2.(table-5)

LOD and LOQ: The limit of detection is an individual analytical method is the smallest amount of analyte in a sample which can be reliably detected by the analytical method. The limit of quantitation is an individual analytical procedure is the smallest amount of analyte in a sample which can be quantitatively determined. LOD and LOQ were calculated using formula.

$$LOD = 3.3(SD)/S \text{ and } LOQ = 3(LOD)$$

LOD and LOQ value of Favipiravir were found be 0.055 and 0.168µg/ml.

TABLES:

Table 1: Results of calibration curve at 356-366nm by Area under curve method

SL NO	Concentration in µg/ml	Absorbance ± Standard deviation*
1	0	0
2	2	0.127±0.0010
3	4	0.228±0.0008
4	6	0.335±0.0012
5	8	0.459±0.0011
6	10	0.561±0.0015
7	12	0.650±0.0013

*Average of six determinations.

Table 2: Regression parameter for Favipiravir at 356-366nm by Area under curve method.

Regression parameter	Results
Range($\mu\text{g/ml}$)	2-12
λ_{max} (nm)	356-366
Regression Equation	$Y = 0.0534X + 0.0107$
Slope(b)	0.0534
Intercept(a)	0.0107
Correlation coefficient(r^2)	0.9984
Sandell's equation	0.0179
Limit of detection($\mu\text{g/ml}$)	0.055
Limit of quantitation($\mu\text{g/ml}$)	0.168

Table 3: Determination of precision results for Favipiravir at 356-366nm by Area under curve method.

Concentration ($\mu\text{g/ml}$)	Intra-day Absorbance \pm Standard deviation*	%RSD**	Inter-day Absorbance \pm Standard deviation*	%RSD**
2	0.127 \pm 0.0010	0.78	0.121 \pm 0.0007	0.57
4	0.228 \pm 0.0008	0.23	0.225 \pm 0.0033	1.46
6	0.335 \pm 0.0012	0.35	0.342 \pm 0.0018	0.52
8	0.459 \pm 0.0011	0.26	0.450 \pm 0.0016	0.35
10	0.561 \pm 0.0015	0.35	0.556 \pm 0.0019	0.34
12	0.650 \pm 0.0013	0.20	0.639 \pm 0.0007	0.10

*Average of six determinations, **percentage relative standard deviation.

Table 4: Determination of Accuracy results for Favipiravir at 356-366nm by Area under curve method.

Spiked Levels	Amount of Sample ($\mu\text{g/ml}$)	Amount of Standard ($\mu\text{g/ml}$)	Amount Recovered	% Recovery \pm Standard deviation*	%RSD**
50	6	3	9.06	100.6 \pm 0.286	0.284
100	6	6	11.83	98.6 \pm 0.223	0.226
150	6	9	15.17	101.1 \pm 0.137	0.135

*Average of six determinations, **percentage relative standard deviation.

Table 5: Determination of Ruggedness results for Favipiravir at 356-366nm by Area under curve method.

Analysts	Analyst 1	Analyst 2
Mean absorbance	0.342	0.342
\pm Standard deviation*	0.0017	0.0008
%RSD	0.49	0.23

*Average of six determinations, **percentage relative standard deviation.

FIGURES:




Fig.2: Area under curve spectrum of Favipiravir at 356-366nm.




Fig.3: Area under curve overlain spectra of Favipiravir showing absorbance at 356-366nm.




Fig.4: Calibration curve of Favipiravir at 356-366nm by Area under curve method.

CONCLUSION:

As per ICH guidelines, the present analytical was carried and met the acceptance criteria. It was concluded that the developed analytical method was simple, specific, accurate, economical and sensitive and can be used for routine analysis of Favipiravir in bulk drug and in pharmaceutical dosage forms.

ACKNOWLEDGEMENT:

We authors wish to thank our management, principal of pharmacy college for providing all facilities in the college.

REFERENCES:

1. Chaudhari P, Waghmare S. An Overview on Analytical Estimation of Favipiravir. *Intl J of Pharm Res and Applications*. 2022 Jun;7(3):2456-4494.
2. V Pruthvi Shree, Zaranappa. A Review of the Analytical methods for the determination of Favipiravir. *Intl J of Pharm Sci and Res*. 2022 May;14(5):2060-2075.
3. Sayyed Nazifa Sabir Ali, Analytical Method Development and Validation and Forced Degradation Stability-Indicating Studies of Favipiravir by RP-HPLC and UV in Bulk and Pharmaceutical Dosage Form. *J of Pharm Res Intl*. 2021;33(48B):254-271.
4. Dr. Sandip D Firke, UV Spectroscopic Method Development and Validation for Estimation of Potent Antiviral Drug Favipiravir. *Int j of Pharma and Res*. 2021 Jul;14(5): 2320-5148.
5. Ramadoss K, Meerasa SS, Satyapal AK, Vijayakumar A, Venugopal V. Quantitative analysis of favipiravir in bulk and pharmaceutical dosage forms using UV visible spectrophotometer. *J of med pharma and allied sciences*. 2023 April;12(2):4410.
6. Bhavar G. development and validation of UV spectrophotometric method for estimation of favipiravir. *Eur Chem Bull*. 2023;12(5):259-269.
7. P Chiranjeevi, Varaprasad Rao, M Bala Naga Priya, P Sireesha. UV-Spectrophotometric method development and validation of Favipiravir in pure and formulation. *UGC Care Grp J*. 2022 Jul;52(6):0378-4568.

8. Ibrahim Bulduk. Comparison of HPLC and UV Spectrophotometric methods for quantification of favipiravir in pharmaceutical formulations. *Iran J of pharma Res.* 2021; 20(3):57-65.
9. Megahed S, Habib A, Hammad S, Kamal A. Chemometric approach based on factorial and box-Behnken designs for determination of Anti coronavirus drug; Favipiravir in bulk and spiked human plasma by green HPLC method. *Turkish J of Anal Chem.* 2021 Dec 12; 3(2):70-8.
10. Vemuri DK, Gundla R, Konduru N, Mallavarapu R, Katari NK. Favipiravir (SARS-CoV-2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC–MS method. *Biomed Chromatogr.* 2022 Jun;36(6):5363.
11. Ibraam E. Mikhail, Heba Elmansi, Fathallah Belal, Adel Ehab Ibrahim. Green micellar solvent – free HPLC and Spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens. *Micro chem J.* 2021 March 15; 165:106189.
12. Balu PA, Paresh MS. Stability-indicating RP HPLC method development for estimation of favipiravir in bulk and pharmaceutical dosage form. *World J of Pharma Res.* 2021 Oct 20;10(14):1444-65.
13. Borkar V, Shahare H, Chandmore K, Rkhibe V, Amruta B, Vidhate S, Patil C, Jain S. Development and Validation of RP-HPLC Method for Estimation of Favipiravir in Bulk and Its Pharmaceutical Dosage Form. (IJFANS) *Int J of Food and Nutr Sci.* 2022;11(2): 2319-1775.
14. Bathula S, Sammaiah G, Warangal T. RP-HPLC method development and validation for determination of favipiravir in pure substances and marketed tablet dosage form. *Int J Of Adv Res in Med & Pharma Sci (IJARMPS).* 2023 Aug;8(4):2455-6998.
15. Nandeeshia Itigimatha, Kailash S, Chadchan, Basappa C. Yallur, Manjunatha D. Hadagali. New analytical methods for the determination of new Anti-viral drug Favipiravir: A potential therapeutic drug against COVID-19 virus, in bulk and dosage forms. *Pharma Che J.* 2023;56(10):5610-1419.
16. Lingabathula S, Jain N. Stability Indicative and Cost-Effective Analytical Method Development and Validation of Favipiravir and Peramivir in Bulk and Pharmaceutical Dosage Form by Using RP-HPLC. *Int J Appl Pharm.* 2021;13(4):265-71.
17. Keerthi G, Ravi Kumar. P, Padmavathi. Y. Development and validation of RP-HPLC Method for quantitative estimation of Favipiravir in bulk and pharmaceutical dosage form. *YMER.* 2022 Jun;21(6):0044-0477.
18. Shinde J, Sharma PK, Sharma J. Development and Validation Of RP-HPLC Method For Estimation of Favipiravir API and Its Tablet Dosage Form Using Quality by Design Approach. *J of Pharma Neg R.* 2023 Jan;13(8):115-26.
19. Nayak AB, Sree PP, Illendula S, Suresh BD, Rao K N. A new analytical method development and validation for the quantitative determination of favipiravir in bulk and pharmaceutical dosage form by RP-HPLC method. *Res gate.* 2023 Feb;22(2):0044-0477.
20. Nadendla R, Abhinandana P. a Validated High-Performance Liquid Chromatographic Method for the Quantification of Favipiravir by PDA Detector. *Int J Life Sci Pharma Res.* 2021;11(2):1818.
21. Chakraborty S, Mondal S. a Green Eco-friendly Analytical Method Development, Validation, and Stress Degradation Studies of Favipiravir in Bulk and Different Tablet Dosages Form by UV-Spectro-photometric and RP-HPLC Methods with their Comparison by Using ANOVA and in-vitro Dissolution Studies. *Int J of Pharma Invt.* 2023 Apr 1;13(2):290-305.
22. Marzouk HM, Rezk MR, Gouda AS, Abdel-Megied AM. A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment;

- application to degradation kinetic studies and in-vitro dissolution profiling. *Micro chem J.* 2022 Jan 1; 172:106917.
23. Sonu A. Varma and Priyanka Yadav, Stability indicating HPLC Method Development and Validation for Estimation of Favipiravir in Pharmaceutical Dosage Form. *WJPPS.* 2021;10(5):1749-1760.
 24. Aydinoglu Marinelli, Sabriye, Bozyel, Metin. Favipiravir determination in pharmaceutical formulation via HPLC chromatographic approach. *Iran J Chem Eng* 2023;42(4):1099-1110.
 25. Roshdy E. Saraya, Sami El Deeb, Baher I. Salman, Adel Ehab Ibrahim. Highly sensitive High-performance thin layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations. *J Sep Sci.* 2022; 45:2582-2590.
 26. ICH Q2A Text on validation of analytical procedures, 1994. <https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf>.
 27. ICH Q2 (R1) Validation of analytical procedure: Text and methodology, 2005. <https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf>.
 28. ICH Q2B: Guidance for Industry: Validation of Analytical Procedures: Methodology U.S Department of Health and Human Services Food and Drug Administration, (CBER), 1996.